Sarepta Therapeutics (NASDAQ:SRPT) announced its earnings results on Thursday. The biotechnology company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.35), Fidelity Earnings reports. The company had revenue of $99.04 million for the quarter, compared to analysts’ expectations of $98.49 million. Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The business’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.15) earnings per share.
NASDAQ SRPT traded up $2.90 during mid-day trading on Friday, reaching $96.28. 2,233,600 shares of the company’s stock traded hands, compared to its average volume of 1,365,711. Sarepta Therapeutics has a 1-year low of $72.05 and a 1-year high of $158.80. The company has a fifty day simple moving average of $84.10 and a 200-day simple moving average of $113.31. The company has a current ratio of 8.81, a quick ratio of 7.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $6.95 billion, a price-to-earnings ratio of -17.63 and a beta of 2.19.
In other Sarepta Therapeutics news, Director Richard Barry acquired 1,300 shares of the stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $122.50 per share, for a total transaction of $159,250.00. Following the purchase, the director now directly owns 3,173,365 shares in the company, valued at $388,737,212.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Kathleen Behrens acquired 2,500 shares of the stock in a transaction on Friday, September 6th. The shares were acquired at an average price of $87.98 per share, with a total value of $219,950.00. Following the purchase, the director now owns 123,167 shares in the company, valued at $10,836,232.66. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 35,752 shares of company stock valued at $3,940,114. 6.60% of the stock is owned by insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: Gap Up Stocks
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.